Non-Hodgkin's Lymphoma Market

• The Non-Hodgkin lymphoma Market Size is anticipated to grow with a significant CAGR during the study period (2020-2034).
• As per the American Cancer Society (2022), NHL is one of the most common cancers in the United States, accounting for about 4% of all cancers. About 80,470 people will be diagnosed with NHL in 2022.
• Non-Hodgkin lymphoma epidemiology is segmented as Total Incident Cases of NHL, Type-specific Incident Cases of NHL, Stage-specific Incident Cases of NHL, Age-specific Incident Cases of NHL, and Treatable Cases of NHL by Line of Therapies] in the Non-Hodgkin lymphoma market report.
• Several Non-Hodgkin lymphoma companies are actively involved in developing therapies for Non-Hodgkin lymphoma, including AbbVie, Genmab, Novartis, Angiocrine Bioscience, Autolus, Zentera Therapeutics, Jiangsu Hengrui Medicine, and others, advancing innovative treatment approaches.

Request for unlocking CAGR of Non-Hodgkin lymphoma Market

DelveInsight’s “Non-Hodgkin lymphoma Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of the NHL, historical and forecasted epidemiology as well as the Non-Hodgkin lymphoma therapeutics market trends in the United States EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The NHL market report provides current treatment practices, emerging drugs, NHL market share of the individual therapies, and current and forecasted NHL market size from 2020-2034, segmented by seven major markets. The report also covers current Non-Hodgkin lymphoma treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Non-Hodgkin lymphoma Treatment Market

The DelveInsight’s NHL market report gives a thorough understanding of Non-Hodgkin lymphoma by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment. Non-Hodgkin lymphoma is a type of cancer that generally develops in the lymph nodes and lymphatic tissue found in organs such as the stomach, intestines or skin. In some cases, NHL involves bone marrow and blood. NHL is not just one disease–it's actually a diverse group of blood cancers that all arise from lymphocytes (white blood cells that are part of the immune system). Lymphoma cells may develop in just one place or in many sites in the body. NHL has many different subtypes which are either indolent (slow-growing) or aggressive (fast-growing). There are about 600 lymph nodes in the body. The most common early sign of NHL is painless swelling of one or more lymph node(s). Most patients with NHL have one or more enlarged lymph nodes in the neck, armpit or groin. Less often, a swollen node appears near the ears, the elbow or in the throat near the tonsils. Occasionally, the disease starts in a site other than the lymph nodes, such as a bone, a lung, the gastrointestinal tract or the skin. In these circumstances, patients may experience symptoms that are associated with that specific site. A cell undergoes a change (mutation) in a lymph node or in some other lymphatic structure. It can start in one of three major types of lymphocytes like B lymphocytes (B-cells), which produce antibodies to help combat infections, T lymphocytes (T-cells), which have several functions, including helping B lymphocytes make antibodies.

Specialists further characterize the NHL subtypes according to how the disease progresses - Aggressive lymphomas are, indolent lymphomas are slow-moving and tend to grow more slowly and have fewer signs and symptoms when first diagnosed.

Non-Hodgkin lymphoma Diagnosis

Non-Hodgkin lymphoma is diagnosed based on detailed patient history, thorough clinical evaluation, and a variety of tests, including a biopsy of an affected lymph node or the bone marrow, blood tests, PET/CT scan, and imaging tests like CAT.

A staging system is a way for members of a cancer care team to sum up the extent of a cancer’s spread. The current staging system for NHL in adults is known as the Lugano classification, which is based on the older Ann Arbor system. The stages are described by roman numerals I through IV (1-4). Limited stage (I or II) lymphomas that affect an organ outside the lymph system (an extranodal organ) have an E added (for example, stage IIE).

Non-Hodgkin lymphoma Treatment

The treatment depends upon the severity and spread rate of the disease. Various types of treatment regimen used to treat NHL, are as like chemotherapy and other drug therapy, radiation therapy (usually combined with chemotherapy), stem cell transplantation, watch-and-wait. If the patient does not respond to these, targeted therapies are used. Non-Hodgkin lymphoma clinical trials explore innovative therapies, including immunotherapies and targeted treatments, aiming to improve survival rates, reduce relapse, and enhance quality of life for affected patients worldwide.

Non-Hodgkin lymphoma Epidemiology 

The Non-Hodgkin lymphoma epidemiology section provides insights into historical and current Non-Hodgkin lymphoma patient pool and forecasted trends for seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Non-Hodgkin lymphoma report also provides the diagnosed patient pool, their trends and assumptions undertaken.

Key findings

• As per the American Cancer Society (2022), NHL is one of the most common cancers in the United States, accounting for about 4% of all cancers. About 80,470 people will be diagnosed with NHL in 2022.
• The Non-Hodgkin lymphoma epidemiology covered in the report provides historical as well as forecasted Non-Hodgkin lymphoma epidemiology [segmented as Total Incident Cases of NHL, Type-specific Incident Cases of NHL, Stage-specific Incident Cases of NHL, Age-specific Incident Cases of NHL, and Treatable Cases of NHL by Line of Therapies] in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020-2034.

Country-wise Non-Hodgkin lymphoma Epidemiology

The epidemiology segment also provides the NHL epidemiology data and findings across the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Non-Hodgkin lymphoma Drug Chapters

The drug chapter segment of the Non-Hodgkin lymphoma report encloses the detailed analysis of Non-Hodgkin lymphoma marketed drugs and late-stage (Phase III and Phase II) Non-Hodgkin lymphoma pipeline drugs. It also helps understand the Non-Hodgkin lymphoma clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases. The Non-Hodgkin Lymphoma drugs market is expanding due to rising incidence rates, advanced targeted therapies, and increased research funding, offering promising treatment options and improved patient outcomes worldwide.

Emerging Non-Hodgkin lymphoma Drugs

The report details the emerging Non-Hodgkin lymphoma therapies under the late and mid-stage of development for Non-Hodgkin lymphoma treatment.

• AUR-105: Aurigene Oncology

AUR-105 by Aurigene Oncology is under development for the treatment of solid tumor, Non Hodgkin Lymphoma, Leukemia or Hodgkin Lymphoma. The drug candidate is administered through oral route. The

drug candidates act by targeting protein arginine methyltransferase 5 (PRMT5). Currently, the drug is in Phase I stage, where it is being assessed for safety, pharmacokinetics, and pharmacodynamics in patients with relapsed advanced malignancies. (NCT05605119/ SURYA1).

• AU-103: Aurigene Oncology

AU-103 by Aurigene Oncology is a highly differentiated oral small molecule inhibitor of CD47. In pre-clinical studies, AUR-103 does not show hemotoxicity. This is in contrast to anti CD47 antibodies, where significant dose-limiting toxicities of anemia, thrombocytopenia, and leukopenia have been observed. Currently , the company is conducting a Phase I, Open Label, Dose-Escalation, First in Human (FIH) Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AUR103 Calcium in Patients With Relapsed Advanced Malignancies (BHARAT-1/ NCT05607199).

Non-Hodgkin lymphoma Market Outlook

The Non-Hodgkin lymphoma market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Non-Hodgkin lymphoma market trends by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology.

This segment gives a thorough detail of the Non-Hodgkin lymphoma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Non-Hodgkin lymphoma market in 7MM is expected to witness a major change in the study period 2020-2034.

Key findings

This section includes a glimpse of the Non-Hodgkin lymphoma market in 7MM.

The United States Non-Hodgkin lymphoma Market Outlook

This section provides the total Non-Hodgkin lymphoma market size and market size by therapies in the United States.

EU4 and the United Kingdom Countries Non-Hodgkin lymphoma Market Outlook

The total Non-Hodgkin lymphoma market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Non-Hodgkin lymphoma Market Outlook

The total Non-Hodgkin lymphoma market size and market size by therapies in Japan is also mentioned. 

Non-Hodgkin lymphoma Drug Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Non-Hodgkin lymphoma market or expected to get launched in the market during the study period 2020-2034. The analysis covers Non-Hodgkin lymphoma market uptake by drugs, patient uptake by therapies, and sales of each drug.  

This will help in understanding the Non-Hodgkin lymphoma drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Non-Hodgkin lymphoma Pipeline Development Activities

The Non-Hodgkin lymphoma pipeline report provides insights into different Non-Hodgkin lymphoma clinical trials within Phase II, and Phase III stages. It also analyses NHL’s key players involved in developing targeted therapeutics.

Non-Hodgkin lymphoma Clinical Trial Development Activities

The Non-Hodgkin lymphoma Clinical Trial report covers detailed information on collaborations, acquisitions, and mergers, licensing patent details, and other information for Non-Hodgkin lymphoma emerging therapies.

Non-Hodgkin lymphoma Reimbursement Scenario

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL Views

To keep up with current epidemiology and market trends, we take KOLs and SMEs' opinions working in the Non-Hodgkin lymphoma domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies and treatment patterns along with Non-Hodgkin lymphoma market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform competitive and market intelligence analysis of the Non-Hodgkin lymphoma market by using various competitive intelligence tools that include – SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Non-Hodgkin lymphoma Market Report

• Descriptive overview of NHL, disease overview, patient journeys, treatment algorithms, diagnosis, and currently available therapies
• Comprehensive insight into the NHL epidemiology and forecasts in the 7MM
• An all-inclusive account of both the current and emerging therapies for NHL, along with the assessment of new therapies, expected to have an impact on the current treatment landscape
• Exhaustive analysis of the NHL market; historical and forecasted covering drug outreach in the 7MM
• Detailed patient based market forecasting determines the trends shaping and driving the global Non-Hodgkin lymphoma market

Non-Hodgkin lymphoma Market Report Highlights

• In the coming years, the Non-Hodgkin lymphoma market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The Non-Hodgkin lymphoma companies and academics are working to assess challenges and seek opportunities that could influence Non-Hodgkin lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition   
• Major players are involved in developing Non-Hodgkin lymphoma therapies. The launch of emerging therapies will significantly impact the Non-Hodgkin lymphoma market
• A better understanding of Non-Hodgkin lymphoma pathogenesis will also contribute to the development of novel therapeutics for NHL
• Our in-depth analysis of the Non-Hodgkin lymphoma pipeline assets across different stages of development (Phase III and Phase II), emerging trends, and comparative analysis of pipeline products with detailed Non-Hodgkin lymphoma clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Non-Hodgkin lymphoma Market Report Insights

• Patient Based NHL Market Forecasting 
• NHL Therapeutic approaches
• NHL pipeline analysis
• NHL market size and trends
• NHL market opportunities
• Impact of Upcoming NHL Therapies

Non-Hodgkin lymphoma Market Report Key Strengths

• 11 years’ forecast
• 7MM coverage
• NHL epidemiology segmentation
• Key cross competition
• KOL views
• NHL drugs uptake

Non-Hodgkin lymphoma Market Report Assessment

• Current NHL treatment practices
• NHL Unmet needs
• NHL pipeline product profiles
• NHL market attractiveness
• NHL Market Drivers
• NHL Market Barriers

Key Questions Answered In The Non-Hodgkin lymphoma Market Report:

Non-Hodgkin lymphoma Market Insights:

• What would be the NHL market growth till 2034, and what will be the resultant market size in 2034?
• What was the Non-Hodgkin lymphoma drug class share (in percentage) distribution in 2020, and how would it look in 2034?
• What would be the Non-Hodgkin lymphoma total market size and market size by therapies across the 7MM during the forecast period (2020-2034)?
• What are the key findings of the market across 7MM, and which country will have the largest Non-Hodgkin lymphoma market size during the forecast period (2020-2034)
• How would the unmet needs affect the Non-Hodgkin lymphoma market dynamics and subsequent analysis of the associated trends?

Non-Hodgkin lymphoma Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of NHL?
• What is the historical and forecasted Non-Hodgkin lymphoma patient pool in 7MM, and where can one observe the highest patient population and growth opportunities? 
• What are the key factors driving the epidemiology trends for seven major markets covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?

Current Non-Hodgkin lymphoma Treatment Scenario, Marketed Drugs, and Emerging Therapies

• What are the current treatment guidelines and treatment options, in addition to approved therapies for Non-Hodgkin lymphoma in the US, Europe, and Japan?
• What are the key collaborations (Industry–Industry, Industry-Academia), mergers and acquisitions, and licensing activities related to Non-Hodgkin lymphoma therapies?
•  What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Non-Hodgkin lymphoma and its status, along with the challenges faced?

Reasons to Buy Non-Hodgkin lymphoma Market Forecast Report

• The patient based market forecasting analysis will help in developing business strategies by understanding trends shaping and driving the Non-Hodgkin lymphoma market
• Organize sales and marketing efforts by identifying the best opportunities for Non-Hodgkin lymphoma in the US, Europe (Germany, France, Italy, and Spain) and the United Kingdom, and Japan
• Identification of strong upcoming players in the market that will help devise strategies that will help in getting ahead of competitors